科研速览 · Science Skim继续刷下去 · Keep skimming →
◇ bioRxiv2026-08-18· cell biology

Inadequate antibody validation places substantial numbers of animal and human tissue samples at risk of waste

M. Biddle, J. Cooper, K. Blades, D. Ruddy, E. M. Krockow, H. Virk

原始摘要(英文原文)· Original abstract
Lack of antibody validation by researchers frequently misdirects biomedical research, yet the ethical consequences, particularly avoidable use of animal and human biological materials, remain unquantified. Using focus groups (n=12), surveys (n=107), and systematic analysis of 785 publications, we examined how researchers select and validate antibodies, and quantified the downstream ethical costs. Antibody selection is substantially influenced by social factors such as previous laboratory use and peer recommendations, while systematic evaluation of performance characteristics remains limited. From a dataset of 614 antibodies subjected to rigorous characterisation using knockout controls, 97 (15.8%) failed across all tested applications; we systematically searched for publications linked to these antibodies. Within the 760 publications (those where validation status could be confirmed), only 120 (15.8%) presented any validation evidence, despite 72.0% of surveyed researchers reporting having used at least one recommended validation method. The remaining 640 papers reported a minimum of 8,064 animal samples and 4,424 human tissue samples used with antibodies of demonstrated poor performance and without evidence of fitness for the specific experimental purpose; we describe these as samples at risk of waste. Reserving the term waste for samples used with reagents since withdrawn from sale, and therefore irreproducible, conservative extrapolation gives lower-bound, order-of-magnitude estimates of millions of animal and human tissue samples consumed globally. Researchers identified time, cost, and lack of supervisor support as primary barriers, whilst strongly supporting open data sharing, dedicated validation funding, and publisher requirements as solutions. These findings provide a first quantification of the ethical costs of inadequate antibody validation and highlight the need for coordinated stakeholder interventions to reduce avoidable biological sample waste in biomedical research.
读原文 · Read the paper ↗

AI 追问PRO

登录后使用 AI 追问

讨论区

登录后参与讨论

相关论文 · Related

Inadequate antibody validation places substantial numbers of animal and human tissue samples at risk of waste — 科研速览 Science Skim